Cargando…

Prognostic Value of Quantitative [(18)F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma

Background: Prognostic biomarkers are pivotal for adequate treatment decision making. The objective of this study was to determine the added prognostic value of quantitative [(18)F]FDG-PET features in patients with metastases from soft tissue sarcoma (STS). Methods: Patients with metastases from STS...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalisvaart, Gijsbert M., Grootjans, Willem, Bovée, Judith V. M. G., Gelderblom, Hans, van der Hage, Jos A., van de Sande, Michiel A. J., van Velden, Floris H. P., Bloem, Johan L., de Geus-Oei, Lioe-Fee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700088/
https://www.ncbi.nlm.nih.gov/pubmed/34943508
http://dx.doi.org/10.3390/diagnostics11122271
_version_ 1784620672073334784
author Kalisvaart, Gijsbert M.
Grootjans, Willem
Bovée, Judith V. M. G.
Gelderblom, Hans
van der Hage, Jos A.
van de Sande, Michiel A. J.
van Velden, Floris H. P.
Bloem, Johan L.
de Geus-Oei, Lioe-Fee
author_facet Kalisvaart, Gijsbert M.
Grootjans, Willem
Bovée, Judith V. M. G.
Gelderblom, Hans
van der Hage, Jos A.
van de Sande, Michiel A. J.
van Velden, Floris H. P.
Bloem, Johan L.
de Geus-Oei, Lioe-Fee
author_sort Kalisvaart, Gijsbert M.
collection PubMed
description Background: Prognostic biomarkers are pivotal for adequate treatment decision making. The objective of this study was to determine the added prognostic value of quantitative [(18)F]FDG-PET features in patients with metastases from soft tissue sarcoma (STS). Methods: Patients with metastases from STS, detected by (re)staging [(18)F]FDG-PET/CT at Leiden University Medical Centre, were retrospectively included. Clinical and histopathological patient characteristics and [(18)F]FDG-PET features (SUVmax, SUVpeak, SUVmean, total lesion glycolysis, and metabolic tumor volume) were analyzed as prognostic factors for overall survival using a Cox proportional hazards model and Kaplan–Meier methods. Results: A total of 31 patients were included. SUVmax and SUVpeak were significantly predictive for overall survival (OS) in a univariate analysis (p = 0.004 and p = 0.006, respectively). Hazard ratios (HRs) were 1.16 per unit increase for SUVmax and 1.20 per unit for SUVpeak. SUVmax and SUVpeak remained significant predictors for overall survival after correction for the two strongest predictive clinical characteristics (number of lesions and performance status) in a multivariate analysis (p = 0.02 for both). Median SUVmax and SUVpeak were 5.7 and 4.9 g/mL, respectively. The estimated mean overall survival in patients with SUVmax > 5.7 g/mL was 14 months; otherwise, it was 39 months (p < 0.001). For patients with SUVpeak > 4.9 g/mL, the estimated mean overall survival was 18 months; otherwise, it was 33 months (p = 0.04). Conclusions: In this study, SUVmax and SUVpeak were independent prognostic factors for overall survival in patients with metastases from STS. These results warrant further investigation of metabolic imaging with [(18)F]FDG-PET/CT in patients with metastatic STS.
format Online
Article
Text
id pubmed-8700088
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87000882021-12-24 Prognostic Value of Quantitative [(18)F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma Kalisvaart, Gijsbert M. Grootjans, Willem Bovée, Judith V. M. G. Gelderblom, Hans van der Hage, Jos A. van de Sande, Michiel A. J. van Velden, Floris H. P. Bloem, Johan L. de Geus-Oei, Lioe-Fee Diagnostics (Basel) Article Background: Prognostic biomarkers are pivotal for adequate treatment decision making. The objective of this study was to determine the added prognostic value of quantitative [(18)F]FDG-PET features in patients with metastases from soft tissue sarcoma (STS). Methods: Patients with metastases from STS, detected by (re)staging [(18)F]FDG-PET/CT at Leiden University Medical Centre, were retrospectively included. Clinical and histopathological patient characteristics and [(18)F]FDG-PET features (SUVmax, SUVpeak, SUVmean, total lesion glycolysis, and metabolic tumor volume) were analyzed as prognostic factors for overall survival using a Cox proportional hazards model and Kaplan–Meier methods. Results: A total of 31 patients were included. SUVmax and SUVpeak were significantly predictive for overall survival (OS) in a univariate analysis (p = 0.004 and p = 0.006, respectively). Hazard ratios (HRs) were 1.16 per unit increase for SUVmax and 1.20 per unit for SUVpeak. SUVmax and SUVpeak remained significant predictors for overall survival after correction for the two strongest predictive clinical characteristics (number of lesions and performance status) in a multivariate analysis (p = 0.02 for both). Median SUVmax and SUVpeak were 5.7 and 4.9 g/mL, respectively. The estimated mean overall survival in patients with SUVmax > 5.7 g/mL was 14 months; otherwise, it was 39 months (p < 0.001). For patients with SUVpeak > 4.9 g/mL, the estimated mean overall survival was 18 months; otherwise, it was 33 months (p = 0.04). Conclusions: In this study, SUVmax and SUVpeak were independent prognostic factors for overall survival in patients with metastases from STS. These results warrant further investigation of metabolic imaging with [(18)F]FDG-PET/CT in patients with metastatic STS. MDPI 2021-12-04 /pmc/articles/PMC8700088/ /pubmed/34943508 http://dx.doi.org/10.3390/diagnostics11122271 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kalisvaart, Gijsbert M.
Grootjans, Willem
Bovée, Judith V. M. G.
Gelderblom, Hans
van der Hage, Jos A.
van de Sande, Michiel A. J.
van Velden, Floris H. P.
Bloem, Johan L.
de Geus-Oei, Lioe-Fee
Prognostic Value of Quantitative [(18)F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma
title Prognostic Value of Quantitative [(18)F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma
title_full Prognostic Value of Quantitative [(18)F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma
title_fullStr Prognostic Value of Quantitative [(18)F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma
title_full_unstemmed Prognostic Value of Quantitative [(18)F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma
title_short Prognostic Value of Quantitative [(18)F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma
title_sort prognostic value of quantitative [(18)f]fdg-pet features in patients with metastases from soft tissue sarcoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700088/
https://www.ncbi.nlm.nih.gov/pubmed/34943508
http://dx.doi.org/10.3390/diagnostics11122271
work_keys_str_mv AT kalisvaartgijsbertm prognosticvalueofquantitative18ffdgpetfeaturesinpatientswithmetastasesfromsofttissuesarcoma
AT grootjanswillem prognosticvalueofquantitative18ffdgpetfeaturesinpatientswithmetastasesfromsofttissuesarcoma
AT boveejudithvmg prognosticvalueofquantitative18ffdgpetfeaturesinpatientswithmetastasesfromsofttissuesarcoma
AT gelderblomhans prognosticvalueofquantitative18ffdgpetfeaturesinpatientswithmetastasesfromsofttissuesarcoma
AT vanderhagejosa prognosticvalueofquantitative18ffdgpetfeaturesinpatientswithmetastasesfromsofttissuesarcoma
AT vandesandemichielaj prognosticvalueofquantitative18ffdgpetfeaturesinpatientswithmetastasesfromsofttissuesarcoma
AT vanveldenflorishp prognosticvalueofquantitative18ffdgpetfeaturesinpatientswithmetastasesfromsofttissuesarcoma
AT bloemjohanl prognosticvalueofquantitative18ffdgpetfeaturesinpatientswithmetastasesfromsofttissuesarcoma
AT degeusoeilioefee prognosticvalueofquantitative18ffdgpetfeaturesinpatientswithmetastasesfromsofttissuesarcoma